Arena Pharmaceuticals has concluded the transfer of the BELVIQ new drug application to clinical research specialist Eisiai.
As a result of the move, Eisai is now the marketing authorisation holder accountable for regulatory activities in the US with regard to the commercialisation of the solution.
However, Arena will carry on in its oversight role for BELVIQ's global development and will work in close liaison with Eisai to formulate a joint development plan for the US.
Lonnel Coats, president and chief executive officer of Eisai, said: "The NDA transfer furthers our commitment to BELVIQ as we prepare to launch in the US and submit applications for approval throughout the Americas."
This deal comes after Eisai announced that the Ministry of Health and Social Development of the Russian Federation has consented its antiepileptic agent Zonergan (zonisamide).
The solution will be used as an adjunctive therapy to treat adults with epilepsy who are affected by partial seizures.